Aurobindo Pharma, a Rs.4,475 crore plus pharma major from Hyderabad, has suffered heavy setback during the second quarter ended September 2011 on account of foreign exchange loss of Rs.185.42 crore as against gain of Rs.76.19 crore in the corresponding period of last year. It incurred a consolidated net loss of Rs.80.16 crore as compared to a net profit of Rs.198.32 crore. The company's consolidated net sales also declined by 3.4 per cent to Rs.1,075 crore from Rs.1,113 crore in the last period. The dossier income declined to Rs.15.31 crore from Rs.69.88 crore. Its EBDITA declined sharply by 54.5 per cent to Rs.120.60 crore from Rs.264.80 crore. The company has redeemed all outstanding FCCBs.


For the first half ended September 2011, Aurobindo's consolidated net sales improved by 5.8 per cent to Rs.2,152 crore from Rs.2,034 crore in the similar period of last year. However, it reported net loss of Rs.202.96 crore as compared to net profit of Rs.249.82 crore. The foreign exchange loss reached at Rs.182 crore as against a gain of Rs.34.42 crore.


The company's standalone net sales declined by 8.8 per cent to Rs.957.69 crore from Rs.1050.43 crore in the corresponding period of last year and it incurred net loss of Rs.41.88 crore as compared to a profit of Rs.214.03 crore. Sales includes exports of Rs.697 crore as compared to Rs.743 crore in the similar period of last year.


The company sub-divided its share of Rs.5 in to 5 equity shares of Rs.1 each with effect from February 11, 2011. During the quarter ended September 2011, the company liquidated its subsidiary Aurobindo Pharma (Bulgaria) EAD.